Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma
The objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative chemo-response score (CRS) in patients with advanced high grade serous ovarian cancer(HGSC) treated with neoadjuvant chemotherapy(NACT). This is a...
Saved in:
| Published in | Gynecologic oncology Vol. 187; pp. 92 - 97 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.08.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative chemo-response score (CRS) in patients with advanced high grade serous ovarian cancer(HGSC) treated with neoadjuvant chemotherapy(NACT).
This is a retrospective cohort study of patients with Stage III-IV HGSC treated with NACT from March 2010 to December 2019 at Princess Margaret Cancer Center, Toronto, Canada. KELIM scores were calculated based on the tool devised by You et al. available online. CRS was assessed using an established 3-tier scoring system. An association analysis was performed to determine if the KELIM score assessed during NACT can predict CRS score at the time of interval cytoreductive surgery(ICS).
172 patients were included in this analysis. Patients with CRS 1–2 had a lower median Platinum Free Interval(PFI) (9.24 vs 13.64 months, p = 0.005), lower median progression free survival(PFS) (14.99 vs 20.29 months, p = 0.003) and lower 5-year overall survival(OS) (63.8% vs 69.7%, p = 0.54) compared to patients with CRS3. Among patients with CRS 1–2(n = 115), 68.7% had KELIM <1, while 56.2% of patients with CRS3 had KELIM ≥1(56.2%), p = 0.0017, suggesting a correlation between the KELIM and CRS scores. Furthermore, patients with KELIM ≥1 and CRS3 had significantly higher PFS compared to other groups(median PFS 28.27 months vs 17.66 months for KELIM ≥1/CRS 1/2; 17.13 months for KELIM <1/CRS 3; and 14.53 months for KELIM <1/CRS 1–2, p = 0.003).
The biochemical KELIM score correlated with the surgical pathologic CRS score and may predict pathological response to chemotherapy. This information can be utilized to tailor and personalize treatment in patients with advanced ovarian malignancy.
•The KELIM score is predictive of chemotherapy response in patients with advanced ovarian cancer who are treated with NACT.•The KELIM score correlates with the pathologic CRS score.•The combination of the KELIM and CRS scores can be used to personalize treatment for patients with advanced ovarian cancer. |
|---|---|
| AbstractList | The objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative chemo-response score (CRS) in patients with advanced high grade serous ovarian cancer(HGSC) treated with neoadjuvant chemotherapy(NACT).
This is a retrospective cohort study of patients with Stage III-IV HGSC treated with NACT from March 2010 to December 2019 at Princess Margaret Cancer Center, Toronto, Canada. KELIM scores were calculated based on the tool devised by You et al. available online. CRS was assessed using an established 3-tier scoring system. An association analysis was performed to determine if the KELIM score assessed during NACT can predict CRS score at the time of interval cytoreductive surgery(ICS).
172 patients were included in this analysis. Patients with CRS 1-2 had a lower median Platinum Free Interval(PFI) (9.24 vs 13.64 months, p = 0.005), lower median progression free survival(PFS) (14.99 vs 20.29 months, p = 0.003) and lower 5-year overall survival(OS) (63.8% vs 69.7%, p = 0.54) compared to patients with CRS3. Among patients with CRS 1-2(n = 115), 68.7% had KELIM <1, while 56.2% of patients with CRS3 had KELIM ≥1(56.2%), p = 0.0017, suggesting a correlation between the KELIM and CRS scores. Furthermore, patients with KELIM ≥1 and CRS3 had significantly higher PFS compared to other groups(median PFS 28.27 months vs 17.66 months for KELIM ≥1/CRS 1/2; 17.13 months for KELIM <1/CRS 3; and 14.53 months for KELIM <1/CRS 1-2, p = 0.003).
The biochemical KELIM score correlated with the surgical pathologic CRS score and may predict pathological response to chemotherapy. This information can be utilized to tailor and personalize treatment in patients with advanced ovarian malignancy. The objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative chemo-response score (CRS) in patients with advanced high grade serous ovarian cancer(HGSC) treated with neoadjuvant chemotherapy(NACT). This is a retrospective cohort study of patients with Stage III-IV HGSC treated with NACT from March 2010 to December 2019 at Princess Margaret Cancer Center, Toronto, Canada. KELIM scores were calculated based on the tool devised by You et al. available online. CRS was assessed using an established 3-tier scoring system. An association analysis was performed to determine if the KELIM score assessed during NACT can predict CRS score at the time of interval cytoreductive surgery(ICS). 172 patients were included in this analysis. Patients with CRS 1–2 had a lower median Platinum Free Interval(PFI) (9.24 vs 13.64 months, p = 0.005), lower median progression free survival(PFS) (14.99 vs 20.29 months, p = 0.003) and lower 5-year overall survival(OS) (63.8% vs 69.7%, p = 0.54) compared to patients with CRS3. Among patients with CRS 1–2(n = 115), 68.7% had KELIM <1, while 56.2% of patients with CRS3 had KELIM ≥1(56.2%), p = 0.0017, suggesting a correlation between the KELIM and CRS scores. Furthermore, patients with KELIM ≥1 and CRS3 had significantly higher PFS compared to other groups(median PFS 28.27 months vs 17.66 months for KELIM ≥1/CRS 1/2; 17.13 months for KELIM <1/CRS 3; and 14.53 months for KELIM <1/CRS 1–2, p = 0.003). The biochemical KELIM score correlated with the surgical pathologic CRS score and may predict pathological response to chemotherapy. This information can be utilized to tailor and personalize treatment in patients with advanced ovarian malignancy. •The KELIM score is predictive of chemotherapy response in patients with advanced ovarian cancer who are treated with NACT.•The KELIM score correlates with the pathologic CRS score.•The combination of the KELIM and CRS scores can be used to personalize treatment for patients with advanced ovarian cancer. The objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative chemo-response score (CRS) in patients with advanced high grade serous ovarian cancer(HGSC) treated with neoadjuvant chemotherapy(NACT).BACKGROUNDThe objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative chemo-response score (CRS) in patients with advanced high grade serous ovarian cancer(HGSC) treated with neoadjuvant chemotherapy(NACT).This is a retrospective cohort study of patients with Stage III-IV HGSC treated with NACT from March 2010 to December 2019 at Princess Margaret Cancer Center, Toronto, Canada. KELIM scores were calculated based on the tool devised by You et al. available online. CRS was assessed using an established 3-tier scoring system. An association analysis was performed to determine if the KELIM score assessed during NACT can predict CRS score at the time of interval cytoreductive surgery(ICS).METHODSThis is a retrospective cohort study of patients with Stage III-IV HGSC treated with NACT from March 2010 to December 2019 at Princess Margaret Cancer Center, Toronto, Canada. KELIM scores were calculated based on the tool devised by You et al. available online. CRS was assessed using an established 3-tier scoring system. An association analysis was performed to determine if the KELIM score assessed during NACT can predict CRS score at the time of interval cytoreductive surgery(ICS).172 patients were included in this analysis. Patients with CRS 1-2 had a lower median Platinum Free Interval(PFI) (9.24 vs 13.64 months, p = 0.005), lower median progression free survival(PFS) (14.99 vs 20.29 months, p = 0.003) and lower 5-year overall survival(OS) (63.8% vs 69.7%, p = 0.54) compared to patients with CRS3. Among patients with CRS 1-2(n = 115), 68.7% had KELIM <1, while 56.2% of patients with CRS3 had KELIM ≥1(56.2%), p = 0.0017, suggesting a correlation between the KELIM and CRS scores. Furthermore, patients with KELIM ≥1 and CRS3 had significantly higher PFS compared to other groups(median PFS 28.27 months vs 17.66 months for KELIM ≥1/CRS 1/2; 17.13 months for KELIM <1/CRS 3; and 14.53 months for KELIM <1/CRS 1-2, p = 0.003).RESULTS172 patients were included in this analysis. Patients with CRS 1-2 had a lower median Platinum Free Interval(PFI) (9.24 vs 13.64 months, p = 0.005), lower median progression free survival(PFS) (14.99 vs 20.29 months, p = 0.003) and lower 5-year overall survival(OS) (63.8% vs 69.7%, p = 0.54) compared to patients with CRS3. Among patients with CRS 1-2(n = 115), 68.7% had KELIM <1, while 56.2% of patients with CRS3 had KELIM ≥1(56.2%), p = 0.0017, suggesting a correlation between the KELIM and CRS scores. Furthermore, patients with KELIM ≥1 and CRS3 had significantly higher PFS compared to other groups(median PFS 28.27 months vs 17.66 months for KELIM ≥1/CRS 1/2; 17.13 months for KELIM <1/CRS 3; and 14.53 months for KELIM <1/CRS 1-2, p = 0.003).The biochemical KELIM score correlated with the surgical pathologic CRS score and may predict pathological response to chemotherapy. This information can be utilized to tailor and personalize treatment in patients with advanced ovarian malignancy.CONCLUSIONThe biochemical KELIM score correlated with the surgical pathologic CRS score and may predict pathological response to chemotherapy. This information can be utilized to tailor and personalize treatment in patients with advanced ovarian malignancy. |
| Author | Piedimonte, Sabrina Lheureux, Stephanie Rouzbahman, Marjan May, Taymaa Murray, Ciara Atenafu, Eshetu G. |
| Author_xml | – sequence: 1 givenname: Sabrina surname: Piedimonte fullname: Piedimonte, Sabrina organization: Division of Gynecologic Oncology, Hopital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada – sequence: 2 givenname: Ciara surname: Murray fullname: Murray, Ciara organization: Department of Pathology, St. James's Hospital, Dublin 8, Ireland – sequence: 3 givenname: Eshetu G. surname: Atenafu fullname: Atenafu, Eshetu G. organization: Department of Biostatistics, University Health Network, Toronto, Ontario, Canada – sequence: 4 givenname: Marjan surname: Rouzbahman fullname: Rouzbahman, Marjan organization: Department of Pathology, University of Health Network, Toronto, Ontario, Canada – sequence: 5 givenname: Stephanie surname: Lheureux fullname: Lheureux, Stephanie organization: Department of Medical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada – sequence: 6 givenname: Taymaa surname: May fullname: May, Taymaa email: tmay1@mgb.org organization: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States of America |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38735145$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc9uEzEQxi1URNPAEyAhH8thg_-sd70HDlVU2qpBXOBsee3ZxtGuvdhOqrwST4nbtByRRrLk-X0zmu-7QGc-eEDoIyUrSmjzZbc6Phx9WDHC6hUpRbo3aEFJJ6pGiu4MLcoPqSQT8hxdpLQjhHBC2Tt0zmXLBa3FAv1Zhxhh1Nn5B5y3gO-vN3ff8eX6ijKBYXST86UZPI46AzbBp6x9xvefcTIhAtbePuvMFqZQRUhzQeC1mfAcwTqTQ0w4DCcqgU8uu4PLR-w8nst88DnhR5e3WNuD9gYsDgcdnfbY6GicD5N-j94Oekzw4eVdol_frn-ub6vNj5u79dWmMpx0uQJtRU_MwPtWaEa7VlorBw66Z6Yf2t5KbqSxQyN61g6M9o0xspOiNkwAayxfosvT3DmG33tIWU0uGRhH7SHsk-JE1DXntHi4RPyEmhhSijCoObpJx6OiRD2FpHbqOST1FJIipUhXVJ9eFuz7Cew_zWsqBfh6AqCceXAQVTLFouKKi2CyssH9d8FfrCSqBQ |
| Cites_doi | 10.1136/ijgc-2020-001640 10.1097/IGC.0000000000000946 10.1016/j.ygyno.2023.05.065 10.3802/jgo.2020.31.e17 10.1097/IGC.0b013e318247727f 10.1158/1078-0432.CCR-20-0054 10.1016/S0959-8049(11)70152-6 10.1097/PGP.0000000000000513 10.1002/ijgo.12376 10.1200/JCO.2014.60.5212 10.1200/JCO.2014.56.3106 10.1016/j.ygyno.2022.10.014 10.1016/j.ygyno.2016.11.001 10.1016/j.ygyno.2019.04.679 10.1016/j.ygyno.2016.11.033 10.1016/j.ygyno.2016.04.026 10.1200/JCO.2019.37.15_suppl.5512 10.1016/S0140-6736(14)62223-6 10.1200/JCO.2002.20.5.1248 10.1111/aogs.13814 |
| ContentType | Journal Article |
| Copyright | 2024 Elsevier Inc. Copyright © 2024 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2024 Elsevier Inc. – notice: Copyright © 2024 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.ygyno.2024.04.009 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1095-6859 |
| EndPage | 97 |
| ExternalDocumentID | 10_1016_j_ygyno_2024_04_009 38735145 S009082582400194X |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAXUO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- AAXKI AFJKZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c309t-ead5b0cf3b75a21978dd8f3eab2cbf7bd83c8cdf65b27f21b6cc89854c25e26d3 |
| IEDL.DBID | AIKHN |
| ISSN | 0090-8258 1095-6859 |
| IngestDate | Tue Sep 17 17:33:41 EDT 2024 Thu Sep 26 20:40:49 EDT 2024 Wed Oct 23 09:59:51 EDT 2024 Sat Aug 10 15:31:48 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Neoadjuvant chemotherapy CA-125 KELIM score CRS score Survival Ovarian cancer |
| Language | English |
| License | Copyright © 2024 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c309t-ead5b0cf3b75a21978dd8f3eab2cbf7bd83c8cdf65b27f21b6cc89854c25e26d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 38735145 |
| PQID | 3054433187 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_3054433187 crossref_primary_10_1016_j_ygyno_2024_04_009 pubmed_primary_38735145 elsevier_sciencedirect_doi_10_1016_j_ygyno_2024_04_009 |
| PublicationCentury | 2000 |
| PublicationDate | August 2024 2024-Aug 2024-08-00 20240801 |
| PublicationDateYYYYMMDD | 2024-08-01 |
| PublicationDate_xml | – month: 08 year: 2024 text: August 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Gynecologic oncology |
| PublicationTitleAlternate | Gynecol Oncol |
| PublicationYear | 2024 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Kessous, Wissing, Piedimonte (bb0065) 2020; 99 Shalowitz, Epstein, Ko, Giuntoli (bb0050) 2016; 142 Piedimonte, Kim, Bernardini (bb0075) 2022; 167 Cohen, Powell, Böhm (bb0080) 2019; 154 Böhm, Faruqi, Said (bb0085) 2015; 33 Horowitz, Miller, Rungruang (bb0015) 2015; 33 May, Stewart, Bernardini (bb0060) 2018; 140 Ferron, Rauglaudre, Chevalier (bb0090) 2019; 37 Kehoe, Hook, Nankivell (bb0025) 2015; 386 von Gruenigen, Huang, Beumer (bb0040) 2017; 144 You, Robelin, Tod (bb0070) 2020; 26 Piedimonte, Gabriela, Brigitte (bb0100) 2022; 32 Colombo, Gadducci, Landoni (bb0105) 2023; 175 Saha, Varughese, Gallagher (bb0055) 2012; 22 Marchetti, Kristeleit, McCormack (bb0045) 2017; 144 Bristow, Tomacruz, Armstrong, Trimble, Montz (bb0010) 2002; 20 Liu, Filippova, Zhou (bb0035) 2020; 31 Vergote, Amant, Kristensen, Ehlen, Reed, Casado (bb0030) 2011; 47 Fagotti, Ferrandina, Vizzielli (bb0020) 2020; 30 May, Comeau, Sun (bb0005) 2017; 27 Ditzel, Strickland, Meserve (bb0095) 2019; 38 Ditzel (10.1016/j.ygyno.2024.04.009_bb0095) 2019; 38 Cohen (10.1016/j.ygyno.2024.04.009_bb0080) 2019; 154 Piedimonte (10.1016/j.ygyno.2024.04.009_bb0100) 2022; 32 Kehoe (10.1016/j.ygyno.2024.04.009_bb0025) 2015; 386 Horowitz (10.1016/j.ygyno.2024.04.009_bb0015) 2015; 33 Ferron (10.1016/j.ygyno.2024.04.009_bb0090) 2019; 37 Kessous (10.1016/j.ygyno.2024.04.009_bb0065) 2020; 99 May (10.1016/j.ygyno.2024.04.009_bb0060) 2018; 140 Colombo (10.1016/j.ygyno.2024.04.009_bb0105) 2023; 175 Fagotti (10.1016/j.ygyno.2024.04.009_bb0020) 2020; 30 Liu (10.1016/j.ygyno.2024.04.009_bb0035) 2020; 31 Marchetti (10.1016/j.ygyno.2024.04.009_bb0045) 2017; 144 Shalowitz (10.1016/j.ygyno.2024.04.009_bb0050) 2016; 142 May (10.1016/j.ygyno.2024.04.009_bb0005) 2017; 27 von Gruenigen (10.1016/j.ygyno.2024.04.009_bb0040) 2017; 144 Vergote (10.1016/j.ygyno.2024.04.009_bb0030) 2011; 47 Piedimonte (10.1016/j.ygyno.2024.04.009_bb0075) 2022; 167 You (10.1016/j.ygyno.2024.04.009_bb0070) 2020; 26 Böhm (10.1016/j.ygyno.2024.04.009_bb0085) 2015; 33 Bristow (10.1016/j.ygyno.2024.04.009_bb0010) 2002; 20 Saha (10.1016/j.ygyno.2024.04.009_bb0055) 2012; 22 |
| References_xml | – volume: 31 year: 2020 ident: bb0035 article-title: Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery publication-title: J. Gynecol. Oncol. contributor: fullname: Zhou – volume: 99 start-page: 933 year: 2020 end-page: 940 ident: bb0065 article-title: CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer publication-title: Acta Obstet. Gynecol. Scand. contributor: fullname: Piedimonte – volume: 27 start-page: 668 year: 2017 end-page: 674 ident: bb0005 article-title: A comparison of survival outcomes in advanced serous ovarian Cancer patients treated with primary Debulking surgery versus neoadjuvant chemotherapy publication-title: Int. J. Gynecol. Cancer contributor: fullname: Sun – volume: 33 start-page: 2457 year: 2015 end-page: 2463 ident: bb0085 article-title: Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in Tubo-ovarian high-grade serous carcinoma publication-title: J. Clin. Oncol. contributor: fullname: Said – volume: 175 start-page: 182 year: 2023 end-page: 189 ident: bb0105 article-title: Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: results of a Delphi study publication-title: Gynecol. Oncol. contributor: fullname: Landoni – volume: 33 start-page: 937 year: 2015 end-page: 943 ident: bb0015 article-title: Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 publication-title: J. Clin. Oncol. contributor: fullname: Rungruang – volume: 142 start-page: 30 year: 2016 end-page: 37 ident: bb0050 article-title: Non-surgical management of ovarian cancer: prevalence and implications publication-title: Gynecol. Oncol. contributor: fullname: Giuntoli – volume: 30 start-page: 1657 year: 2020 end-page: 1664 ident: bb0020 article-title: Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) publication-title: Int. J. Gynecol. Cancer contributor: fullname: Vizzielli – volume: 144 start-page: 57 year: 2017 end-page: 60 ident: bb0045 article-title: Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: a single institution retrospective review publication-title: Gynecol. Oncol. contributor: fullname: McCormack – volume: 140 start-page: 247 year: 2018 end-page: 252 ident: bb0060 article-title: The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer publication-title: Int. J. Gynaecol. Obstet. contributor: fullname: Bernardini – volume: 26 start-page: 4625 year: 2020 end-page: 4632 ident: bb0070 article-title: CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial publication-title: Clin. Cancer Res. contributor: fullname: Tod – volume: 154 start-page: 441 year: 2019 end-page: 448 ident: bb0080 article-title: Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data publication-title: Gynecol. Oncol. contributor: fullname: Böhm – volume: 167 start-page: 417 year: 2022 end-page: 422 ident: bb0075 article-title: Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer publication-title: Gynecol. Oncol. contributor: fullname: Bernardini – volume: 20 start-page: 1248 year: 2002 end-page: 1259 ident: bb0010 article-title: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis publication-title: J. Clin. Oncol. contributor: fullname: Montz – volume: 32 start-page: A106 year: 2022 ident: bb0100 article-title: EP145/#106 application of machine learning in endometrial cancer: a systematic review publication-title: Int. J. Gynecol. Cancer contributor: fullname: Brigitte – volume: 47 start-page: S88 year: 2011 end-page: S92 ident: bb0030 article-title: Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer publication-title: Eur. J. Cancer (Oxford, England: 1990) contributor: fullname: Casado – volume: 37 start-page: 5512 year: 2019 ident: bb0090 article-title: Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study publication-title: J. Clin. Oncol. contributor: fullname: Chevalier – volume: 144 start-page: 459 year: 2017 end-page: 467 ident: bb0040 article-title: Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG oncology/gynecologic oncology group study publication-title: Gynecol. Oncol. contributor: fullname: Beumer – volume: 22 start-page: 566 year: 2012 end-page: 572 ident: bb0055 article-title: Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery publication-title: Int. J. Gynecol. Cancer contributor: fullname: Gallagher – volume: 386 start-page: 249 year: 2015 end-page: 257 ident: bb0025 article-title: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial publication-title: Lancet (London, England) contributor: fullname: Nankivell – volume: 38 start-page: 230 year: 2019 end-page: 240 ident: bb0095 article-title: Assessment of a chemotherapy response score (CRS) system for Tubo-ovarian high-grade serous carcinoma (HGSC) publication-title: Int. J. Gynecol. Pathol. contributor: fullname: Meserve – volume: 30 start-page: 1657 year: 2020 ident: 10.1016/j.ygyno.2024.04.009_bb0020 article-title: Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) publication-title: Int. J. Gynecol. Cancer doi: 10.1136/ijgc-2020-001640 contributor: fullname: Fagotti – volume: 27 start-page: 668 year: 2017 ident: 10.1016/j.ygyno.2024.04.009_bb0005 article-title: A comparison of survival outcomes in advanced serous ovarian Cancer patients treated with primary Debulking surgery versus neoadjuvant chemotherapy publication-title: Int. J. Gynecol. Cancer doi: 10.1097/IGC.0000000000000946 contributor: fullname: May – volume: 175 start-page: 182 year: 2023 ident: 10.1016/j.ygyno.2024.04.009_bb0105 article-title: Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: results of a Delphi study publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2023.05.065 contributor: fullname: Colombo – volume: 31 year: 2020 ident: 10.1016/j.ygyno.2024.04.009_bb0035 article-title: Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery publication-title: J. Gynecol. Oncol. doi: 10.3802/jgo.2020.31.e17 contributor: fullname: Liu – volume: 22 start-page: 566 year: 2012 ident: 10.1016/j.ygyno.2024.04.009_bb0055 article-title: Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery publication-title: Int. J. Gynecol. Cancer doi: 10.1097/IGC.0b013e318247727f contributor: fullname: Saha – volume: 26 start-page: 4625 year: 2020 ident: 10.1016/j.ygyno.2024.04.009_bb0070 article-title: CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0054 contributor: fullname: You – volume: 47 start-page: S88 issue: Suppl. 3 year: 2011 ident: 10.1016/j.ygyno.2024.04.009_bb0030 article-title: Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer publication-title: Eur. J. Cancer (Oxford, England: 1990) doi: 10.1016/S0959-8049(11)70152-6 contributor: fullname: Vergote – volume: 38 start-page: 230 year: 2019 ident: 10.1016/j.ygyno.2024.04.009_bb0095 article-title: Assessment of a chemotherapy response score (CRS) system for Tubo-ovarian high-grade serous carcinoma (HGSC) publication-title: Int. J. Gynecol. Pathol. doi: 10.1097/PGP.0000000000000513 contributor: fullname: Ditzel – volume: 32 start-page: A106 year: 2022 ident: 10.1016/j.ygyno.2024.04.009_bb0100 article-title: EP145/#106 application of machine learning in endometrial cancer: a systematic review publication-title: Int. J. Gynecol. Cancer contributor: fullname: Piedimonte – volume: 140 start-page: 247 year: 2018 ident: 10.1016/j.ygyno.2024.04.009_bb0060 article-title: The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer publication-title: Int. J. Gynaecol. Obstet. doi: 10.1002/ijgo.12376 contributor: fullname: May – volume: 33 start-page: 2457 year: 2015 ident: 10.1016/j.ygyno.2024.04.009_bb0085 article-title: Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in Tubo-ovarian high-grade serous carcinoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.60.5212 contributor: fullname: Böhm – volume: 33 start-page: 937 year: 2015 ident: 10.1016/j.ygyno.2024.04.009_bb0015 article-title: Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.3106 contributor: fullname: Horowitz – volume: 167 start-page: 417 year: 2022 ident: 10.1016/j.ygyno.2024.04.009_bb0075 article-title: Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2022.10.014 contributor: fullname: Piedimonte – volume: 144 start-page: 57 year: 2017 ident: 10.1016/j.ygyno.2024.04.009_bb0045 article-title: Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: a single institution retrospective review publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2016.11.001 contributor: fullname: Marchetti – volume: 154 start-page: 441 year: 2019 ident: 10.1016/j.ygyno.2024.04.009_bb0080 article-title: Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2019.04.679 contributor: fullname: Cohen – volume: 144 start-page: 459 year: 2017 ident: 10.1016/j.ygyno.2024.04.009_bb0040 article-title: Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG oncology/gynecologic oncology group study publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2016.11.033 contributor: fullname: von Gruenigen – volume: 142 start-page: 30 year: 2016 ident: 10.1016/j.ygyno.2024.04.009_bb0050 article-title: Non-surgical management of ovarian cancer: prevalence and implications publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2016.04.026 contributor: fullname: Shalowitz – volume: 37 start-page: 5512 year: 2019 ident: 10.1016/j.ygyno.2024.04.009_bb0090 article-title: Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2019.37.15_suppl.5512 contributor: fullname: Ferron – volume: 386 start-page: 249 year: 2015 ident: 10.1016/j.ygyno.2024.04.009_bb0025 article-title: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(14)62223-6 contributor: fullname: Kehoe – volume: 20 start-page: 1248 year: 2002 ident: 10.1016/j.ygyno.2024.04.009_bb0010 article-title: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.20.5.1248 contributor: fullname: Bristow – volume: 99 start-page: 933 year: 2020 ident: 10.1016/j.ygyno.2024.04.009_bb0065 article-title: CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer publication-title: Acta Obstet. Gynecol. Scand. doi: 10.1111/aogs.13814 contributor: fullname: Kessous |
| SSID | ssj0003012 |
| Score | 2.4891653 |
| Snippet | The objective of this study is to assess the correlation between the pre-operative CA125 Elimination rate constant K(KELIM) score and the intraoperative... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 92 |
| SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use CA-125 CA-125 Antigen - blood Carcinoma, Ovarian Epithelial - drug therapy Carcinoma, Ovarian Epithelial - pathology Carcinoma, Ovarian Epithelial - surgery Chemotherapy, Adjuvant Cohort Studies CRS score Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - surgery Cytoreduction Surgical Procedures Female Humans KELIM score Membrane Proteins Middle Aged Neoadjuvant chemotherapy Neoadjuvant Therapy Neoplasm Staging Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Progression-Free Survival Retrospective Studies Survival |
| Title | Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma |
| URI | https://dx.doi.org/10.1016/j.ygyno.2024.04.009 https://www.ncbi.nlm.nih.gov/pubmed/38735145 https://www.proquest.com/docview/3054433187/abstract/ |
| Volume | 187 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbJBkovpe9uH0GFHlqoG0cPSz4uS8K2JjmUhu7N6OWwoZGX9SaQS35Qf2VnLDtQaHsoGIwfsoRnPPPJ-maGkHeCM-6VVJkyKmSAb22mhXYZCyXLfelUE3BF9-S0WJyJL0u53CHzMRYGaZWD7U82vbfWw5mD4W0erFcrjPHFct1SIwsSpuLLXbIH7kiICdmbfa4Wp3cGGXQ4JQ3vo6alHpMP9TSvm_ObiEGATPQpT5GY-GcH9TcA2jui44fkwYAg6SwN8hHZCfExuXcyrJE_IT_nWHADKW7xnAK8o9URWCj6fj4DlEHDj76MF4qDYpYI6hJA3NLqA-0wpyU10fftQJyXbbZJJNowXuzoeoN9YZUe2jbprg5p8KkOBV1FOiRr7Sj-5aUjzYC21zAxN5E6rF8U20vzlJwdH32bL7KhIkPmeF5uM1A7aXPXcKukAVuntPe64cFY5myjrNfcaeebQlqmGnZoC-d0qaVwTAZWeP6MTGIbwwtCG15KY4yE-RQXQTCrC557eGhThgCYako-jmKo1ynxRj0y0i7qXmo1Sq3OYcvLKSlGUdW_6U8NruHfDd-Ogq3hy8LlEhNDe9XVYAkFxpNpNSXPk8TvRsK1whAI-fJ_u31F7uNRohK-JpPt5iq8AXiztftk99Pt4f6gxLivvn6vfgFeuf4d |
| link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKkYAL4pulfAwSB5AIDXYcO8dq1Wphuz210t4s27GrRdRZbbZIvfCD-JX12AkICTgg5RTHiZU3GT_Hb2YIeVMxylrBRSG0cEXkt6aQlbQFdQ0t28YK73BHd3FSz86qz0u-3CHTMRYGZZWD788-PXnr4cz-8Db316sVxvhiuW4uUQUZl-LLG-QmsgHUdX34_kvnES04pwxPMdNcjqmHksjr6vwqYAggrVLCU5Ql_nl6-hv9TNPQ0T1yd-CPcJCHeJ_suPCA3FoMO-QPyY8plttAgVs4h0juYH4Y_RO8nR5EjgHuayrihWAA5ogAm-nhFubvoMeMlqBDm_pFMC-6YpMltG5s7GG9wWdhjR7ofL6qRxF8rkIBqwBDqtYe8B8vjCID6L7FZbkOYLF6Uegu9CNydnR4Op0VQz2GwrKy2RbR6LgprWdGcB09nZBtKz1z2lBrvDCtZFba1tfcUOHpR1NbKxvJK0u5o3XLHpPd0AX3lIBnDdda87iaYpWrqJE1K9t4U984FxnVhLwfYVDrnHZDjXq0LyqhphA1VcajbCakHqFSv1mPihPDvzu-HoFV8bvCzRIdXHfZq-gHK4wmk2JCnmTEf46ESYEBEPzZ_z72Fbk9O10cq-NPJ_M9cgdbsqjwOdndbi7di0h0tuZlMuRruhD9Tw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Correlating+the+KELIM+%28CA125+elimination+rate+constant+K%29+score+and+the+chemo-response+score+as+predictors+of+chemosensitivity+in+patients+with+advanced+ovarian+carcinoma&rft.jtitle=Gynecologic+oncology&rft.au=Piedimonte%2C+Sabrina&rft.au=Murray%2C+Ciara&rft.au=Atenafu%2C+Eshetu+G&rft.au=Rouzbahman%2C+Marjan&rft.date=2024-08-01&rft.issn=1095-6859&rft.eissn=1095-6859&rft.volume=187&rft.spage=92&rft_id=info:doi/10.1016%2Fj.ygyno.2024.04.009&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |